Literature DB >> 16415118

S-2-pentyl-4-pentynoic hydroxamic acid and its metabolite s-2-pentyl-4-pentynoic acid in the NMRI-exencephaly-mouse model: pharmacokinetic profiles, teratogenic effects, and histone deacetylase inhibition abilities of further valproic acid hydroxamates and amides.

Daniel Eikel1, Katrin Hoffmann, Karolin Zoll, Alfonso Lampen, Heinz Nau.   

Abstract

Structure-activity relationship studies of valproic acid (VPA) derivatives have revealed a quantitative correlation between histone deacetylase (HDAC) inhibition and induction of neural tube defects (NTDs) in the NMRI-exencephaly-mouse model, but this correlation has been, so far, limited to congeners with a carboxylic acid function. Whereas the classical HDAC inhibitor trichostatin A is active only as a hydroxamate but not as a carboxylic acid, we found that neither VPA amides nor hydroxamates inhibit HDACs, but can cause NTDs; e.g., 2-pentyl-4-pentynoic hydroxamic acid with its S-enantiomer being the potent teratogen. We therefore investigated the hypothesis that hydroxamic acid derivatives of VPA might be metabolized in vivo and may possibly be pro-teratogenic, as had been shown for valpromide but not valproic hydroxamic acid. We developed two stereoselective quantification methods based on chiral derivatization of VPA hydroxamates with (1R,2S,5R)-(-)-menthylchloroformate and carboxylic acid derivatives with (S)-(-)-1-naphthylethylamine, followed by gas chromatography-nitrogen phosphor detector analysis of biological samples. We then determined the pharmacokinetic profiles of S-2-pentyl-4-pentynoic hydroxamic acid and of S-2-pentyl-4-pentynoic acid in mice. S-2-Pentyl-4-pentynoic hydroxamic acid was found to be extensively metabolized to the corresponding carboxylic acid without affecting the stereochemistry at position C2. Furthermore, the metabolite S-2-pentyl-4-pentynoic acid was found to be very stable in vivo, with an extended half-life of 4.2 h compared with that of VPA, 1.4 h. Comparison of the individual HDAC inhibition abilities of additional VPA amides and hydroxamates, as measured by cellular and enzymatic assays, led us to the conclusion that both classes of VPA derivatives can be pro-teratogenic.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16415118     DOI: 10.1124/dmd.105.008078

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  9 in total

1.  Potent neuroprotective effects of novel structural derivatives of valproic acid: potential roles of HDAC inhibition and HSP70 induction.

Authors:  Yan Leng; Zoya Marinova; Marcos A Reis-Fernandes; Heinz Nau; De-Maw Chuang
Journal:  Neurosci Lett       Date:  2010-04-13       Impact factor: 3.046

2.  Effect of Inhibiting Histone Deacetylase with Short-Chain Carboxylic Acids and Their Hydroxamic Acid Analogs on Vertebrate Development and Neuronal Chromatin.

Authors:  Daniel M Fass; Rishita Shah; Balaram Ghosh; Krista Hennig; Stephanie Norton; Wen-Ning Zhao; Surya A Reis; Peter S Klein; Ralph Mazitschek; Rebecca L Maglathlin; Timothy A Lewis; Stephen J Haggarty
Journal:  ACS Med Chem Lett       Date:  2010-10-08       Impact factor: 4.345

3.  The embryonic stem cell test as tool to assess structure-dependent teratogenicity: the case of valproic acid.

Authors:  Christian Riebeling; Ralph Pirow; Klaus Becker; Roland Buesen; Daniel Eikel; Johanna Kaltenhäuser; Frauke Meyer; Heinz Nau; Birgitta Slawik; Anke Visan; Jutta Volland; Horst Spielmann; Andreas Luch; Andrea Seiler
Journal:  Toxicol Sci       Date:  2011-01-11       Impact factor: 4.849

4.  Inhibition of class II histone deacetylases in the spinal cord attenuates inflammatory hyperalgesia.

Authors:  Guang Bai; Dong Wei; Shiping Zou; Ke Ren; Ronald Dubner
Journal:  Mol Pain       Date:  2010-09-07       Impact factor: 3.395

5.  Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease.

Authors:  Ashok Sriram; Herbert E Ward; Anhar Hassan; Sanjay Iyer; Kelly D Foote; Ramon L Rodriguez; Nikolaus R McFarland; Michael S Okun
Journal:  J Neurol       Date:  2012-09-25       Impact factor: 4.849

6.  Ascorbic acid reverses valproic acid-induced inhibition of hoxa2 and maintains glutathione homeostasis in mouse embryos in culture.

Authors:  B Zhang; X Wang; A J Nazarali
Journal:  Cell Mol Neurobiol       Date:  2009-08-05       Impact factor: 5.046

7.  Valproate reverses stress-induced somatic hyperalgesia and visceral hypersensitivity by up-regulating spinal 5-HT2C receptor expression in female rats.

Authors:  Gang-Zhu Xu; Yang Xue; Si-Qi Wei; Jia-Heng Li; Richard J Traub; Mao-De Wang; Dong-Yuan Cao
Journal:  Neuropharmacology       Date:  2019-12-26       Impact factor: 5.250

8.  Analysis of neuroprotective effects of valproic acid on primary motor neurons in monoculture or co-cultures with astrocytes or Schwann cells.

Authors:  D Ragancokova; K Jahn; A Kotsiari; F Schlesinger; K Haastert; M Stangel; S Petri; K Krampfl
Journal:  Cell Mol Neurobiol       Date:  2009-03-28       Impact factor: 5.046

9.  Effects of the histone deacetylase inhibitor valproic acid on human pericytes in vitro.

Authors:  Jakob Karén; Alejandro Rodriguez; Tomas Friman; Lennart Dencker; Christian Sundberg; Birger Scholz
Journal:  PLoS One       Date:  2011-09-22       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.